John Z Metcalfe1, Elizabeth Streicher2, Grant Theron2, Rebecca E Colman3, Christopher Allender4, Darrin Lemmer4, Rob Warren2, David M Engelthaler4. 1. 1 Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California. 2. 2 DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, and SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. 3. 3 Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, San Diego, San Diego, California; and. 4. 4 Translational Genomics Research Institute, Flagstaff, Arizona.
Abstract
RATIONALE: Minority drug-resistant Mycobacterium tuberculosis subpopulations can be associated with phenotypic resistance but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays. OBJECTIVES: To determine the role of targeted next-generation sequencing in resolving these minor variant subpopulations. METHODS: We used single molecule overlapping reads (SMOR), a targeted next-generation sequencing approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance-determining regions (study group). Isolates also underwent single-colony selection on antibiotic-containing agar, blinded to sequencing results. As a positive control, isolates with multiple colocalizing chromatogram peaks were also analyzed (control group). MEASUREMENTS AND MAIN RESULTS: Among 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49%) and 45 (33%) of 135 total heteroresistant RAVs at frequencies less than 5% and less than 1% of the total mycobacterial population, respectively. In the study group, SMOR detected minor resistant variant subpopulations in 80% (n = 20/25) of isolates with no Sanger-identified RAVs (median subpopulation size, 1.0%; interquartile range, 0.2-3.9%). Single-colony selection on drug-containing media corroborated SMOR results for 90% (n = 18/20) of RAV-containing specimens, and the absence of RAVs in 60% (n = 3/5) of isolates. Overall, Sanger sequencing was concordant with SMOR for 77% (n = 53/69) of macroheteroresistant (5-95% total population), but only 5% of microheteroresistant (<5%) subpopulations (n = 3/66) across both groups. CONCLUSIONS: Cryptic minor variant mycobacterial subpopulations exist below the resolving capability of current drug susceptibility testing methodologies, and may explain an important proportion of false-negative resistance determinations.
RATIONALE: Minority drug-resistant Mycobacterium tuberculosis subpopulations can be associated with phenotypic resistance but are poorly detected by Sanger sequencing or commercial molecular diagnostic assays. OBJECTIVES: To determine the role of targeted next-generation sequencing in resolving these minor variant subpopulations. METHODS: We used single molecule overlapping reads (SMOR), a targeted next-generation sequencing approach that dramatically reduces sequencing error, to analyze primary cultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for which Sanger sequencing found no resistance-associated variants (RAVs) within respective resistance-determining regions (study group). Isolates also underwent single-colony selection on antibiotic-containing agar, blinded to sequencing results. As a positive control, isolates with multiple colocalizing chromatogram peaks were also analyzed (control group). MEASUREMENTS AND MAIN RESULTS: Among 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49%) and 45 (33%) of 135 total heteroresistant RAVs at frequencies less than 5% and less than 1% of the total mycobacterial population, respectively. In the study group, SMOR detected minor resistant variant subpopulations in 80% (n = 20/25) of isolates with no Sanger-identified RAVs (median subpopulation size, 1.0%; interquartile range, 0.2-3.9%). Single-colony selection on drug-containing media corroborated SMOR results for 90% (n = 18/20) of RAV-containing specimens, and the absence of RAVs in 60% (n = 3/5) of isolates. Overall, Sanger sequencing was concordant with SMOR for 77% (n = 53/69) of macroheteroresistant (5-95% total population), but only 5% of microheteroresistant (<5%) subpopulations (n = 3/66) across both groups. CONCLUSIONS: Cryptic minor variant mycobacterial subpopulations exist below the resolving capability of current drug susceptibility testing methodologies, and may explain an important proportion of false-negative resistance determinations.
Authors: Frank A Post; Paul A Willcox; Barun Mathema; Lafras M Steyn; Karen Shean; Srinivas V Ramaswamy; Edward A Graviss; Elena Shashkina; Barry N Kreiswirth; Gilla Kaplan Journal: J Infect Dis Date: 2004-05-28 Impact factor: 5.226
Authors: Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan Journal: Science Date: 2006-06-30 Impact factor: 47.728
Authors: Philippe Roumagnac; François-Xavier Weill; Christiane Dolecek; Stephen Baker; Sylvain Brisse; Nguyen Tran Chinh; Thi Anh Hong Le; Camilo J Acosta; Jeremy Farrar; Gordon Dougan; Mark Achtman Journal: Science Date: 2006-11-24 Impact factor: 47.728
Authors: S Hofmann-Thiel; J van Ingen; K Feldmann; L Turaev; G T Uzakova; G Murmusaeva; D van Soolingen; H Hoffmann Journal: Eur Respir J Date: 2008-10-01 Impact factor: 16.671
Authors: John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Renee Penaloza; Christopher Allender; Darrin Lemmer; Robin M Warren; David M Engelthaler Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Palwasha Y Khan; Tom A Yates; Muhammad Osman; Robin M Warren; Yuri van der Heijden; Nesri Padayatchi; Edward A Nardell; David Moore; Barun Mathema; Neel Gandhi; Vegard Eldholm; Keertan Dheda; Anneke C Hesseling; Valerie Mizrahi; Roxana Rustomjee; Alexander Pym Journal: Lancet Infect Dis Date: 2018-12-13 Impact factor: 25.071
Authors: David M Engelthaler; Elizabeth M Streicher; Erin J Kelley; Christopher J Allender; Kristin Wiggins; Dulce Jimenez; Darrin Lemmer; Eric Vittinghoff; Grant Theron; Frederick A Sirgel; Robin M Warren; John Z Metcalfe Journal: Am J Respir Cell Mol Biol Date: 2019-12 Impact factor: 6.914
Authors: Nicola M Zetola; Sanghyuk S Shin; Qiao Wang; Chawangwa Modongo; Christopher Allender; David M Engelthaler; Robin M Warren Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Inge Roof; Rana Jajou; Miranda Kamst; Arnout Mulder; Albert de Neeling; Rianne van Hunen; Wim van der Hoek; Dick van Soolingen Journal: J Clin Microbiol Date: 2018-10-25 Impact factor: 5.948
Authors: Sanghyuk S Shin; Chawangwa Modongo; Yeonsoo Baik; Christopher Allender; Darrin Lemmer; Rebecca E Colman; David M Engelthaler; Robin M Warren; Nicola M Zetola Journal: J Infect Dis Date: 2018-11-05 Impact factor: 5.226
Authors: Fernanda Maruri; Yan Guo; Amondrea Blackman; Yuri F van der Heijden; Peter F Rebeiro; Timothy R Sterling Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 9.079